                         SEQUENCE LISTING

<110>  MERCK SHARP & DOHME CORP.
       Homet Moreno, Blance
       Altura, Rachel A.
       Cai, Mingmei
       Diede, Scott J.
       Healy, Jane Anne
       Ibrahim, Nageatte
       Williams, Sybil M. G.
 
<120>  METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF 
       AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT 
       ANTIBODY

<130>  24843-WO-PCT

<150>  US 62/985,645
<151>  2020-03-05

<150>  US 63/043,888
<151>  2020-06-25

<160>  112   

<170>  PatentIn version 3.5

<210>  1
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VL-CDR1

<400>  1

Arg Ala Ser Lys Gly Val Ser Thr Ser Gly Tyr Ser Tyr Leu His 
1               5                   10                  15  


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VL-CDR2

<400>  2

Leu Ala Ser Tyr Leu Glu Ser 
1               5           


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VL-CDR3

<400>  3

Gln His Ser Arg Asp Leu Pro Leu Thr 
1               5                   


<210>  4
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VL

<400>  4

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  5
<211>  218
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, light chain

<400>  5

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105                 110         


Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 
        115                 120                 125             


Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 
    130                 135                 140                 


Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 
145                 150                 155                 160 


Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 
                165                 170                 175     


Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 
            180                 185                 190         


His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 
        195                 200                 205             


Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215             


<210>  6
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VH-CDR1

<400>  6

Asn Tyr Tyr Met Tyr 
1               5   


<210>  7
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VH-CDR1

<400>  7

Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 
1               5                   10                  15      


Asn 
    


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VH-CDR3

<400>  8

Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr 
1               5                   10      


<210>  9
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, VH

<400>  9

Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  10
<211>  447
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pembrolizumab, heavy chain

<400>  10

Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 
    210                 215                 220                 


Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 
225                 230                 235                 240 


Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 
                245                 250                 255     


Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 
            260                 265                 270         


Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 
        275                 280                 285             


Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 
    290                 295                 300                 


Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 
305                 310                 315                 320 


Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 
                325                 330                 335     


Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 
            340                 345                 350         


Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 
        355                 360                 365             


Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 
    370                 375                 380                 


Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 
385                 390                 395                 400 


Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 
                405                 410                 415     


Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 
            420                 425                 430         


His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440                 445         


<210>  11
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VH-CDR1

<400>  11

Gly Phe Thr Phe Ser Asp Asn Trp 
1               5               


<210>  12
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VH-CDR2

<400>  12

Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr 
1               5                   10  


<210>  13
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VH-CDR3

<400>  13

Thr Ala Gln Phe Ala Tyr 
1               5       


<210>  14
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VL-CDR1

<400>  14

Glu Asn Ile Tyr Gly Gly 
1               5       


<210>  15
<211>  0
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VL-CDR2

<400>  15
000
<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VL-CDR3

<400>  16

Gln Asn Val Leu Arg Ser Pro Phe Thr 
1               5                   


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VL-CDR3

<400>  17

Gln Asn Val Leu Ser Arg His Pro Gly 
1               5                   


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VL-CDR3

<400>  18

Gln Asn Val Leu Ser Ser Arg Pro Gly 
1               5                   


<210>  19
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VH 8D2/8D2 (RE)

<400>  19

Glu Val Lys Leu Asp Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Asn 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Asn Leu Arg Gly Glu Asp Met Gly Ile Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ala 
        115 


<210>  20
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VL 8D2/8D2 (RE)

<400>  20

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Gly Thr Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Phe Gly Ala Thr Asn Leu Ala Asp Gly Met Ser Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Arg Gln Tyr Ser Leu Lys Ile Ser Ser Leu His Pro 
65                  70                  75                  80  


Asp Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105     


<210>  21
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody VL-CDR1

<400>  21

Arg Ala Ser Glu His Ile Tyr Ser Tyr Leu Ser 
1               5                   10      


<210>  22
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2

<400>  22

Asn Ala Lys Thr Leu Ala Glu 
1               5           


<210>  23
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR3

<400>  23

Gln His His Phe Gly Ser Pro Leu Thr 
1               5                   


<210>  24
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL

<400>  24

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu His Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln His His Phe Gly Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 
            100                 105         


<210>  25
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, light chain

<400>  25

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu His Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln His His Phe Gly Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  26
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR1

<400>  26

Ser Tyr Val Met His 
1               5   


<210>  27
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2

<400>  27

Tyr Ile Asp Pro Tyr Asn Asp Gly Ala Lys Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  28
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3

<400>  28

Gly Gly Pro Tyr Gly Trp Tyr Phe Asp Val 
1               5                   10  


<210>  29
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH

<400>  29

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asp Pro Tyr Asn Asp Gly Ala Lys Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Leu Thr Ser Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Pro Tyr Gly Trp Tyr Phe Asp Val Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  30
<211>  449
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, heavy chain

<400>  30

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asp Pro Tyr Asn Asp Gly Ala Lys Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Leu Thr Ser Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Pro Tyr Gly Trp Tyr Phe Asp Val Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 
        115                 120                 125             


Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 
    130                 135                 140                 


Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 
145                 150                 155                 160 


Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 
                165                 170                 175     


Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 
            180                 185                 190         


Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 
        195                 200                 205             


Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 
    210                 215                 220                 


Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 
225                 230                 235                 240 


Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 
                245                 250                 255     


Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 
            260                 265                 270         


Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 
        275                 280                 285             


Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 
    290                 295                 300                 


Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 
305                 310                 315                 320 


Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 
                325                 330                 335     


Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 
            340                 345                 350         


Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 
        355                 360                 365             


Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 
    370                 375                 380                 


Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 
385                 390                 395                 400 


Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 
                405                 410                 415     


Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 
            420                 425                 430         


Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 
        435                 440                 445             


Lys 
    


<210>  31
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VL-CDR1

<400>  31

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  32
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VL-CDR2

<400>  32

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  33
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VL-CDR3

<400>  33

Gln Gln Ser Ser Asn Trp Pro Arg Thr 
1               5                   


<210>  34
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VL

<400>  34

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  35
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, light chain

<400>  35

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  36
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VH-CDR1

<400>  36

Asn Ser Gly Met His 
1               5   


<210>  37
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VH-CDR2

<400>  37

Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  38
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VH-CDR3

<400>  38

Asn Asp Asp Tyr 
1               


<210>  39
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, VH

<400>  39

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  40
<211>  440
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Nivolumab, heavy chain

<400>  40

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser 
        115                 120                 125             


Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 
    130                 135                 140                 


Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 
145                 150                 155                 160 


Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 
                165                 170                 175     


Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys 
            180                 185                 190         


Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp 
        195                 200                 205             


Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala 
    210                 215                 220                 


Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
225                 230                 235                 240 


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
                245                 250                 255     


Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val 
            260                 265                 270         


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
        275                 280                 285             


Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
    290                 295                 300                 


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 
305                 310                 315                 320 


Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
                325                 330                 335     


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr 
            340                 345                 350         


Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 
        355                 360                 365             


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
    370                 375                 380                 


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
385                 390                 395                 400 


Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe 
                405                 410                 415     


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
            420                 425                 430         


Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440 


<210>  41
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VH 8D2H1L1

<400>  41

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Gly Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  42
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VL 8D2H1L1

<400>  42

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Thr Asn Leu Ala Ser Gly Met Ser Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Lys Ile Ser Ser Leu His Pro 
65                  70                  75                  80  


Asp Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  43
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VH 8D2H2L2

<400>  43

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Gly Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  44
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VL 8D2H2L2 and 8D2H2L2,  VARIANT 1

<400>  44

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Thr Asn Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  45
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VH 8D2H2L2, VARIANT 1

<400>  45

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Gly Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  46
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VH 8D2H3L3

<400>  46

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Glu Tyr Ala Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  47
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VL 8D2H3L3

<400>  47

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Thr Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  48
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VH 8D2H2L15

<400>  48

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Thr Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  49
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VL 8D2H2L15

<400>  49

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Thr Asn Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Arg His Pro 
                85                  90                  95      


Gly Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  50
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VH 8D2H2L17VL

<400>  50

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Gly Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  51
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, VL 8D2H2L17

<400>  51

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Thr Asn Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Ser Arg Pro 
                85                  90                  95      


Gly Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  52
<211>  445
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, Full Heavy Chain, 8D2H2L2 VARIANT 1

<400>  52

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Asn 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Gly Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Gln Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 
        115                 120                 125             


Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 
    130                 135                 140                 


Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 
145                 150                 155                 160 


Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 
                165                 170                 175     


Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 
            180                 185                 190         


Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 
        195                 200                 205             


Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 
    210                 215                 220                 


Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 
225                 230                 235                 240 


Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 
                245                 250                 255     


Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 
            260                 265                 270         


Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 
        275                 280                 285             


Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 
    290                 295                 300                 


Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 
305                 310                 315                 320 


Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 
                325                 330                 335     


Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 
            340                 345                 350         


Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 
        355                 360                 365             


Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 
    370                 375                 380                 


Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 
385                 390                 395                 400 


Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 
                405                 410                 415     


Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 
            420                 425                 430         


His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        435                 440                 445 


<210>  53
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, Full Light Chain, 8D2H2L2 VARIANT 1

<400>  53

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Ile Tyr Gly Gly 
            20                  25                  30          


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Thr Asn Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Arg Ser Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  54
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, CDRL1 (Ipilimumab)

<400>  54

Arg Ala Ser Gln Ser Val Gly Ser Ser Tyr Leu Ala 
1               5                   10          


<210>  55
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, CDRL2 (Ipilimumab)

<400>  55

Gly Ala Phe Ser Arg Ala Thr 
1               5           


<210>  56
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, CDRL3 (Ipilimumab)

<400>  56

Gly Ala Phe Ser Arg Ala Thr Gln Gln Tyr Gly Ser Ser Pro Trp Thr 
1               5                   10                  15      


<210>  57
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4, CDRH1 (Ipilimumab)

<400>  57

Ser Tyr Thr Met His 
1               5   


<210>  58
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  58

Tyr Ile Asp Pro Tyr Asn Asp Gly Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  59
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  59

Tyr Ile Asp Pro Tyr Asn Arg Gly Ala Lys Tyr Asn Glu Lys Phe Gly 
1               5                   10                  15      


<210>  60
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  60

Tyr Ile Asp Pro Tyr Asn Leu Gly Ala Lys Tyr Asn Glu Lys Phe Gly 
1               5                   10                  15      


<210>  61
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  61

Tyr Ile Asp Pro Tyr Asn Lys Gly Ala Lys Tyr Asn Glu Lys Phe Gly 
1               5                   10                  15      


<210>  62
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  62

Tyr Ile Asp Pro Tyr Asn Phe Gly Ala Lys Tyr Asn Glu Lys Phe Gly 
1               5                   10                  15      


<210>  63
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  63

Tyr Ile Asp Pro Tyr Asn Ser Gly Ala Lys Tyr Asn Glu Lys Phe Gly 
1               5                   10                  15      


<210>  64
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  64

Tyr Ile Asp Pro Tyr Asn Tyr Gly Ala Lys Tyr Asn Glu Lys Phe Gly 
1               5                   10                  15      


<210>  65
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  65

Tyr Ile Asp Pro Tyr Asn Val Gly Ala Lys Tyr Asn Glu Lys Phe Gly 
1               5                   10                  15      


<210>  66
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  66

Tyr Ile Asp Pro Tyr Asn Asp Arg Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  67
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  67

Tyr Ile Asp Pro Tyr Asn Asp Asn Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  68
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  68

Tyr Ile Asp Pro Tyr Asn Asp Gln Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  69
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  69

Tyr Ile Asp Pro Tyr Asn Asp Glu Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  70
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  70

Tyr Ile Asp Pro Tyr Asn Asp Leu Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  71
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  71

Tyr Ile Asp Pro Tyr Asn Asp Lys Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  72
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  72

Tyr Ile Asp Pro Tyr Asn Asp Ser Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  73
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  73

Tyr Ile Asp Pro Tyr Asn Asp Tyr Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  74
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  74

Tyr Ile Asp Pro Tyr Asn Asp Val Ala Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  75
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 variant

<400>  75

Tyr Ile Asp Pro Tyr Asn Asp Gly Ala Lys Tyr Ser Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  76
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR2 consensus


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is D, R, L, K, F, S, Y or V

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is G, R, N, Q, E, L K, S, Y or V

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa is N, A or S

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is E or Q

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K or Q

<400>  76

Tyr Ile Asp Pro Tyr Asn Xaa Xaa Ala Lys Tyr Xaa Xaa Lys Phe Xaa 
1               5                   10                  15      


Gly 
    


<210>  77
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  77

Gly Gly Pro Tyr Gly Ala Tyr Phe Asp Val 
1               5                   10  


<210>  78
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  78

Gly Gly Pro Tyr Gly Asp Tyr Phe Asp Val 
1               5                   10  


<210>  79
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  79

Gly Gly Pro Tyr Gly Glu Tyr Phe Asp Val 
1               5                   10  


<210>  80
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  80

Gly Gly Pro Tyr Gly Phe Tyr Phe Asp Val 
1               5                   10  


<210>  81
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  81

Gly Gly Pro Tyr Gly Gly Tyr Phe Asp Val 
1               5                   10  


<210>  82
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  82

Gly Gly Pro Tyr Gly Ile Tyr Phe Asp Val 
1               5                   10  


<210>  83
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  83

Gly Gly Pro Tyr Gly Lys Tyr Phe Asp Val 
1               5                   10  


<210>  84
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  84

Gly Gly Pro Tyr Gly Asn Tyr Phe Asp Val 
1               5                   10  


<210>  85
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  85

Gly Gly Pro Tyr Gly Gln Tyr Phe Asp Val 
1               5                   10  


<210>  86
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  86

Gly Gly Pro Tyr Gly Arg Tyr Phe Asp Val 
1               5                   10  


<210>  87
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  87

Gly Gly Pro Tyr Gly Ser Tyr Phe Asp Val 
1               5                   10  


<210>  88
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  88

Gly Gly Pro Tyr Gly Thr Tyr Phe Asp Val 
1               5                   10  


<210>  89
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  89

Gly Gly Pro Tyr Gly Val Tyr Phe Asp Val 
1               5                   10  


<210>  90
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 variant

<400>  90

Gly Gly Pro Tyr Gly Tyr Tyr Phe Asp Val 
1               5                   10  


<210>  91
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VH-CDR3 consensus


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is W, A, D, E, F, G, I, K, N, Q, R, S, T, V or Y

<400>  91

Gly Gly Pro Tyr Gly Xaa Tyr Phe Asp Val 
1               5                   10  


<210>  92
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  92

Ala Ala Lys Thr Leu Ala Glu 
1               5           


<210>  93
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  93

Tyr Ala Lys Thr Leu Ala Glu 
1               5           


<210>  94
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  94

Trp Ala Lys Thr Leu Ala Glu 
1               5           


<210>  95
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  95

Ser Ala Lys Thr Leu Ala Glu 
1               5           


<210>  96
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  96

Thr Ala Lys Thr Leu Ala Glu 
1               5           


<210>  97
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  97

Ile Ala Lys Thr Leu Ala Glu 
1               5           


<210>  98
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  98

Val Ala Lys Thr Leu Ala Glu 
1               5           


<210>  99
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  99

Asn Asn Lys Thr Leu Ala Glu 
1               5           


<210>  100
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  100

Asn Ile Lys Thr Leu Ala Glu 
1               5           


<210>  101
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  101

Asn Leu Leu Thr Leu Ala Glu 
1               5           


<210>  102
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  102

Asn Thr Lys Thr Leu Ala Glu 
1               5           


<210>  103
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 variant

<400>  103

Asn Val Lys Thr Leu Ala Glu 
1               5           


<210>  104
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TIGIT antibody, VL-CDR2 consensus


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is N, A, V, W, S, T, R, H G, I or V

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is A, N, I, L, T or V

<400>  104

Xaa Xaa Lys Thr Leu Ala Glu 
1               5           


<210>  105
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 CDRH2 (Ipilimumab)

<400>  105

Phe Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  106
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 CDRH3 (Ipilimumab)

<400>  106

Thr Gly Trp Leu Gly Pro Phe Asp Tyr 
1               5                   


<210>  107
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VH/VR in Heavy chain (Ipilimumab)

<400>  107

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Thr Phe Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Thr Gly Trp Leu Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  108
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 VL/VR in Light chain (Ipilimumab)

<400>  108

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Phe Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  109
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 Heavy Chain (Ipilimumab)

<400>  109

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Thr Phe Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Thr Gly Trp Leu Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
225                 230                 235                 240 


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
                245                 250                 255     


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
            260                 265                 270         


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
        275                 280                 285             


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 
    290                 295                 300                 


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
305                 310                 315                 320 


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
                325                 330                 335     


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
            340                 345                 350         


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 
        355                 360                 365             


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
    370                 375                 380                 


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
385                 390                 395                 400 


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
                405                 410                 415     


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
            420                 425                 430         


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        435                 440                 445             


<210>  110
<211>  215
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CTLA4 Light Chain (Ipilimumab)

<400>  110

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Phe Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 
            100                 105                 110         


Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 
        115                 120                 125             


Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 
    130                 135                 140                 


Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 
145                 150                 155                 160 


Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 
                165                 170                 175     


Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 
            180                 185                 190         


Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 
        195                 200                 205             


Ser Phe Asn Arg Gly Glu Cys 
    210                 215 


<210>  111
<211>  244
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A recombinant protein for human TIGIT

<400>  111

Met Arg Trp Cys Leu Leu Leu Ile Trp Ala Gln Gly Leu Arg Gln Ala 
1               5                   10                  15      


Pro Leu Ala Ser Gly Met Met Thr Gly Thr Ile Glu Thr Thr Gly Asn 
            20                  25                  30          


Ile Ser Ala Glu Lys Gly Gly Ser Ile Ile Leu Gln Cys His Leu Ser 
        35                  40                  45              


Ser Thr Thr Ala Gln Val Thr Gln Val Asn Trp Glu Gln Gln Asp Gln 
    50                  55                  60                  


Leu Leu Ala Ile Cys Asn Ala Asp Leu Gly Trp His Ile Ser Pro Ser 
65                  70                  75                  80  


Phe Lys Asp Arg Val Ala Pro Gly Pro Gly Leu Gly Leu Thr Leu Gln 
                85                  90                  95      


Ser Leu Thr Val Asn Asp Thr Gly Glu Tyr Phe Cys Ile Tyr His Thr 
            100                 105                 110         


Tyr Pro Asp Gly Thr Tyr Thr Gly Arg Ile Phe Leu Glu Val Leu Glu 
        115                 120                 125             


Ser Ser Val Ala Glu His Gly Ala Arg Phe Gln Ile Pro Leu Leu Gly 
    130                 135                 140                 


Ala Met Ala Ala Thr Leu Val Val Ile Cys Thr Ala Val Ile Val Val 
145                 150                 155                 160 


Val Ala Leu Thr Arg Lys Lys Lys Ala Leu Arg Ile His Ser Val Glu 
                165                 170                 175     


Gly Asp Leu Arg Arg Lys Ser Ala Gly Gln Glu Glu Trp Ser Pro Ser 
            180                 185                 190         


Ala Pro Ser Pro Pro Gly Ser Cys Val Gln Ala Glu Ala Ala Pro Ala 
        195                 200                 205             


Gly Leu Cys Gly Glu Gln Arg Gly Glu Asp Cys Ala Glu Leu His Asp 
    210                 215                 220                 


Tyr Phe Asn Val Leu Ser Tyr Arg Ser Leu Gly Asn Cys Ser Phe Phe 
225                 230                 235                 240 


Thr Glu Thr Gly 
                


<210>  112
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A recombinant protein for human CTLA4

<400>  112

Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly 
1               5                   10                  15      


Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu 
            20                  25                  30          


Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val 
        35                  40                  45              


Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp 
    50                  55                  60                  


Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile 
65                  70                  75                  80  


Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu 
                85                  90                  95      


Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln 
            100                 105                 110         


Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 
        115                 120                 125 


